Servier India Private Limited

What Servier India Private Limited does

Servier India Private Limited is a wholly-owned subsidiary of Servier Group, a French pharmaceutical company governed by the non-profit Foundation International de Recherche Servier (FIRS). Founded in 1985 and operating in India since 1986, the company is headquartered in Mumbai with a workforce of approximately 580 employees and a pan-India field force engaging 28,000 healthcare professionals. The company focuses on four therapeutic areas: cardiometabolism, neuroscience, oncology, and venous diseases, offering a portfolio of 30+ branded pharmaceutical products including established brands such as Diamicron (gliclazide for diabetes), Coversyl (perindopril for hypertension), Coralan (ivabradine for cardiovascular conditions), Daflon (flavonoid fraction for venous diseases), and Flavedon (trimetazidine).

The company's core product lines span cardiovascular and diabetes treatments (the largest segment by product count), venous disease therapies, neuroscience medicines, and a growing oncology portfolio anchored by Onivyde (liposomal irinotecan) and the 2025 launch of Ivosidenib (Tibsovo®) for IDH1-mutated cancers, with Vorasidenib pending final CDSCO approval. Servier India benefits from its parent's global R&D infrastructure, with over 20% of Servier Group's brand-name revenue reinvested into R&D annually, and from the group's vertical integration including 16 production centers and 98% in-house synthesis of active ingredients in France.

The business model is a traditional branded pharmaceutical sales model: Servier India generates revenue through one-time product sales distributed via a direct field force of scientifically trained professionals who engage healthcare professionals. The company does not publicly disclose pricing. It supports its commercial model with disease awareness websites (Angina Awareness India, #BecauseIsayso, #Vmove), social media campaigns, and HCP education portals (Servier CardioMedical Hub, Servier Vein Academy). The company owns no external funding rounds, has no subsidiaries, and is governed entirely by its parent Servier Group.

Name

Servier India Private Limited

Legal name

Servier India Private Limited

Website

https://servier.in

Company type

Private

Founded year

1985

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Servier India Private Limited is a Mumbai-based pharmaceutical subsidiary of France's Servier Group, employing approximately 580 staff and serving 28,000 healthcare professionals across India with branded medicines in cardiometabolism, neuroscience, oncology, and venous diseases.

Ownership category

akta.pro rank

Product category

Branded Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

akta.pro secondary industries

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Pharmaceutical products
• Cardiometabolic medicines
• Oncology therapies
• Venous disease treatments
• Neuroscience medicines

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Pharmaceutical Product Sales: Servier India generates revenue through sale of branded pharmaceutical products across cardiometabolism, neuroscience, oncology, and venous diseases therapeutic areas. The company sells products through its field force to healthcare professionals across India.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Servier India Private Limited manufactures, markets, and distributes branded pharmaceutical products in India across four therapeutic areas: cardiometabolism (cardiovascular and diabetes treatments such as Coversyl, Diamicron, Coralan, Flavedon, and Dapaser Mex), neuroscience (Stablon, Trivastal, Arcalion), venous diseases (Daflon), and oncology (Onivyde, Ivosidenib/Tibsovo, Vorasidenib). The company reaches approximately 28,000 healthcare professionals across India through a dedicated scientific field force, with products offered in multiple dosage strengths and formulations including standard, modified, and extended-release variants.

Product overview

Servier India Private Limited is a pharmaceutical company offering a diverse portfolio of branded medicines across three core therapeutic areas: Cardiometabolism (cardiovascular and diabetes treatments), Neuroscience, and Oncology. The product portfolio includes cardiovascular medicines such as Coralan® (ivabradine), Coversyl® (perindopril), Natrilam®/Natrilix® (indapamide/amlodipine combinations), and Flavedon® (trimetazidine); diabetes treatments including Diamicron® (gliclazide) and Dapaser® Mex (dapagliflozin/metformin combinations); venous disease treatments such as Daflon® (flavonoid fraction); neuroscience medicines like Stablon® (tianeptine) and Trivastal® L.A. (piribedil); and oncology products including Onivyde (pegylated liposomal irinotecan) and newly launched Ivosidenib (Tibsovo®) and Vorasidenib. Many products are offered in multiple dosage strengths and formulation variants including standard release, modified release (MR), extended release (XR), and single pill combinations (SPCs). The company also offers healthcare professional portals including Servier CardioMedical Hub and Servier Vein Academy for medical education.

Differentiator

Problem solved

Functional benefit

Brands

• Servier CardioMedical Hub: Global website for medical updates and events in cardiology with international expert speakers, live webinars, online learning on demand, congress symposia and updates on scientific evidence.
• Servier Vein Academy

Products and services

• Coversyl® (Perindopril erbumine tablets)
• Diamicron® (Gliclazide tablets)
• Coralan® (Ivabradine tablets)
• Flavedon® (Trimetazidine tablets)
• Daflon® (Micronized Purified Flavonoid Fraction tablets)
• Natrilam® / Natrilix® SR (Indapamide and Amlodipine combinations)
• Dapaser® Mex (Dapagliflozin and Metformin combinations)
• Stablon® (Tianeptine Sodium tablets)
• Trivastal® L.A. (Piribedil sustained release tablets)
• Arcalion® (Sulbutiamine tablets)
• Onivyde (Pegylated Liposomal Irinotecan)
• Tibsovo® (Ivosidenib)
• Vorasidenib Tablets 10 mg & 40 mg
• Coversyl® AM and Coversyl® PLUS (Perindopril combinations)
• Triplixam® (Triple combination cardiovascular tablet)
• Servier CardioMedical Hub
• Servier Vein Academy

Named customers1 record

Segments4 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Partnerships

Three partnerships are on record, tiered core and minor.

• Academic Research InstitutionscoreStrategic or Co-development PartnerServier maintains partnerships with academic research institutions for drug discovery and development, particularly in oncology and autoimmune diseases. These collaborations involve joint research programs and knowledge sharing to advance therapeutic innovation.
• Biotechnology CompaniescoreStrategic or Co-development PartnerServier partners with biotechnology companies for development of new drugs, including partnerships in immunology research with companies such as ILTOO Pharma (systemic lupus erythematosus) and OSE Immunotherapeutics (Sjögren's disease), and Symphogen (monoclonal antibodies) for oncology.
• International Society of HypertensionminorGTM or Marketing PartnerServier supports the global blood pressure screening initiative of the International Society of Hypertension through the social media campaign #BecauseIsayso, supporting patient awareness efforts.

Scale indicators8 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Abbott India: Indian subsidiary of Abbott with strong cardiology and chronic-care franchises across therapeutic categories. Comparable multinational affiliate with branded pharma portfolio and field-force model.
• Roche Products India: Indian affiliate of Swiss multinational Roche, focused on specialty pharmaceuticals and oncology. Comparable in oncology launches and specialty-pharma distribution to HCPs in India.
• AstraZeneca Pharma India: Indian arm of AstraZeneca with deep cardiovascular (Crestor, Brilinta) and growing oncology franchises. Closely comparable MNC affiliate in cardiometabolic and oncology therapeutic areas.
• Novartis India: Indian subsidiary of Swiss multinational Novartis with strong cardiology and specialty medicine portfolios. Comparable multinational pharma affiliate with branded product model.
• Sanofi India: Indian subsidiary of French multinational Sanofi with a strong cardiometabolic and diabetes franchise (insulins, cardiovascular brands). Highly comparable multinational affiliate operating a field-force model across India.
• MSD Pharmaceuticals (India): Indian arm of Merck Sharp & Dohme with focus on specialty pharma, oncology, and chronic disease therapies. Comparable MNC affiliate with branded prescription portfolio targeting HCPs.
• Bayer Pharmaceuticals (India): Indian operations of Bayer, including cardiology and specialty pharmaceutical products. Comparable multinational pharma affiliate with branded portfolio across therapeutic areas.
• Boehringer Ingelheim India: Indian arm of German multinational Boehringer Ingelheim, with leading cardiometabolic products (jardiance type SGLT2 inhibitors, Pradaxa). Directly comparable MNC with primary focus on cardiometabolic disease.

Broad incumbents

• Torrent Pharmaceuticals: Large Indian-headquartered pharma company with significant presence in cardiology and chronic-disease segments. Comparable in cardiometabolic therapy area but operates as a domestic Indian pharma incumbent rather than MNC affiliate.
• Pfizer India: Indian subsidiary of Pfizer with broad branded pharmaceutical portfolio across therapeutic areas. Comparable multinational affiliate, though significantly larger and broader than Servier India.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/becauseIsaysoindia
• LinkedInlinkedin.com/company/serdia-pharmaceuticals-i-ltd.

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Servier India Private Limited